Sun Pharmaceutical Industries Financial Statements

Name: Sun Pharmaceutical Industries Financials — historical data
Creator: StockeZee

For Mar 2026, Sun Pharmaceutical Industries reported revenue of ₹58,462 crore and net profit of ₹11,479 crore. Return on equity stands at 16.00%. Profit & loss, balance sheet and cash flow across 9 reported years are below.

Updated 31 Jul 2026Source: NSE & BSE company filingsNifty 50 constituent

Latest year revenue: ₹58,462 Cr
EBITDA: ₹17,731 Cr
Operating margin: 30.33%
Profit after tax: ₹11,479 Cr
Net margin: 19.64%
EPS: ₹47.84
Latest year: Mar 2026
Years reported: 9

Sun Pharmaceutical Industries profit & loss

Reported annual performance for Sun Pharmaceutical Industries, oldest to newest. Figures in ₹ crore unless a row states otherwise.

Sun Pharmaceutical Industries annual profit and loss statement. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue from Operations	26,489	29,066	32,838	33,498	38,654	43,886	48,497	52,578	58,462
Sales Growth YoY %	—	9.73%	12.98%	2.01%	15.39%	13.53%	10.51%	8.42%	11.19%
Other Income	839	1,025	636	836	922	635	1,354	1,965	1,972
Total Income	27,328	30,091	33,473	34,334	39,576	44,520	49,851	54,543	60,434
Cost of Goods Sold (COGS)	7,425	7,869	9,230	8,690	10,352	10,662	10,663	10,747	11,544
Cost of Materials Consumed	4,463	5,783	5,515	6,153	7,049	7,778	6,904	6,449	7,389
Purchases of Stock-in-Trade	2,731	2,519	3,414	3,175	3,410	3,572	3,466	4,148	3,812
Changes in Inventories	231	-433	301	-638	-108	-687	292	150	343
Gross Profit	19,065	21,197	23,607	24,808	28,303	33,224	37,834	41,831	46,918
Gross Margin %	71.97%	72.93%	71.89%	74.06%	73.22%	75.7%	78.01%	79.56%	80.25%
Total Operating Expenses	13,457	14,889	16,617	16,317	17,905	21,577	24,811	26,559	29,187
Employee Benefit Expense	5,367	5,967	6,362	6,862	7,301	8,296	9,429	9,973	11,419
Other Expenses	8,090	8,922	10,255	9,454	10,604	13,281	15,382	16,586	17,768
EBITDA	5,608	6,308	6,990	8,491	10,398	11,647	13,023	15,272	17,731
OPM %	21.17%	21.7%	21.29%	25.35%	26.9%	26.54%	26.85%	29.05%	30.33%
Total Non-Operating Expenses	1,067	1,094	2,095	-2,085	-2,296	2,530	2,301	2,129	1,969
Depreciation & Amortisation	1,500	1,753	2,053	2,080	2,144	2,529	2,557	2,575	2,938
Finance Costs	518	555	303	141	127	172	238	231	339
Exceptional Items (Before Tax)	-951	-1,214	-261	-4,306	-4,567	-171	-494	-678	-1,307
Profit Before Tax (PBT)	3,479	3,810	5,010	2,799	4,481	9,408	11,088	13,752	15,119
Tax Expense	845	601	823	515	1,076	848	1,439	2,772	3,554
Current Tax	591	601	823	515	1,076	848	1,439	2,772	3,554
Deferred Tax	254	0	0	0	0	0	0	0	0
Effective Tax %	24.29%	15.77%	16.42%	18.39%	24%	9.01%	12.98%	20.16%	23.51%
Total Profit for Period	2,608	3,208	4,172	2,272	3,389	8,513	9,610	10,965	11,509
Less: Non-controlling Interests	447	542	407	-631	117	39	34	36	29
Net Profit (Owner's PAT)	2,162	2,665	3,765	2,904	3,273	8,474	9,576	10,929	11,479
Net Profit Margin %	8.16%	9.17%	11.47%	8.67%	8.47%	19.31%	19.75%	20.79%	19.64%
PAT Growth YoY %	—	23.31%	41.25%	-22.87%	12.7%	158.91%	13.01%	14.12%	5.04%
Earnings Per Share (EPS)	₹9.01	₹11.11	₹15.69	₹12.1	₹13.64	₹35.32	₹39.91	₹45.55	₹47.84
Diluted Shares Outstanding (Cr.)	240	240	240	240	240	240	240	240	240
Profit/Loss from Associates	-25	-1	-15	-12	-17	-48	-38	-15	-56
Other Comprehensive Income (Net of Tax)	523	1,680	2,121	-146	557	2,257	1,142	912	3,827
Expenses	23,849	26,281	28,464	31,534	35,095	35,112	38,763	40,791	45,315
Material Cost %	16.85%	19.9%	16.8%	18.37%	18.24%	17.72%	14.24%	12.27%	12.64%
Employee Cost %	20.26%	20.53%	19.38%	20.49%	18.89%	18.9%	19.44%	18.97%	19.53%
Other Cost %	30.54%	30.7%	31.23%	28.22%	27.43%	30.26%	31.72%	31.55%	30.39%
Interest Coverage (x)	7.94	8.2	16.31	45.33	64.81	53.01	43.89	54.88	43.65

Sun Pharmaceutical Industries revenue and profit trend

Reported annual revenue and net profit, oldest to newest. Two panels because the two measures live on different scales — one shared axis would distort both.

Sun Pharmaceutical Industries balance sheet

Assets, liabilities and shareholders' equity as reported, in Schedule III order. Figures in ₹ crore unless a row states otherwise.

Sun Pharmaceutical Industries annual balance sheet with assets, liabilities and equity. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Equity	44,723	49,125	49,480	51,066	59,315	67,106	72,486	83,880
Equity Share Capital	240	240	240	240	240	240	240	240
Reserves & Surplus	41,169	45,025	46,223	47,771	55,755	63,427	71,978	83,330
Equity Method Investments	243	243	261	266	389	443	449	—
Total Equity	44,723	49,125	49,480	51,066	59,315	67,106	72,486	83,880
Non-Current Liabilities	2,632	3,421	2,041	1,533	1,521	1,373	1,420	2,283
Long-term Borrowings	1,523	2,029	898	230	—	1	3	31
Deferred Tax Liabilities	104	58	45	32	32	155	192	378
Non-Current Provisions	430	511	327	369	343	414	465	512
Other Non-Current Liabilities	571	781	752	634	583	500	394	370
Non-Current Financial Liabilities	1,526	2,071	918	498	564	304	369	1,024
Current Liabilities	17,340	15,706	16,146	17,201	19,906	16,984	18,194	22,622
Short-term Borrowings	8,371	5,549	2,445	701	6,198	2,844	1,867	4,050
Trade Payables	4,148	4,094	3,974	4,479	5,682	5,653	6,184	7,334
Current Financial Liabilities	13,546	10,888	10,656	7,171	13,601	10,130	10,136	14,140
Other Current Financial Liabilities	1,027	1,245	4,237	1,991	1,721	1,632	2,085	2,756
Other Current Liabilities	734	646	728	703	643	1,084	1,170	1,188
Current Provisions	2,932	3,970	4,583	9,148	5,354	5,358	6,155	5,944
Liabilities Held for Sale	—	—	—	—	1	1	—	—
Current Tax Liabilities	127	202	179	178	309	412	733	1,350
Total Liabilities	19,971	19,128	18,187	18,734	21,428	18,357	19,615	24,905
Total Non-Current Assets	33,625	36,598	37,225	34,785	40,860	41,988	39,476	44,894
Property, Plant & Equipment (PPE)	10,027	10,567	10,235	10,371	10,390	10,192	10,036	11,114
Capital Work-in-Progress	911	659	937	798	963	1,108	1,234	1,381
Intangible Assets	5,853	5,798	5,030	5,539	5,317	4,420	3,611	11,875
Non-Current Investments	3,709	5,003	6,222	4,949	5,068	5,999	4,249	3,789
Loans – Non-Current	17	1	1	1	1	1	3	2
Other Non-Current Assets	3,774	4,004	3,970	2,800	2,679	2,759	961	1,116
Non-Current Financial Assets	3,805	5,108	6,318	5,075	5,234	6,117	4,429	3,857
Net Fixed Assets	16,792	17,024	16,202	16,708	16,671	15,720	14,881	24,370
Total Current Assets	31,069	31,654	30,442	35,015	39,862	43,433	52,594	63,860
Inventories	7,886	7,875	8,997	8,997	10,513	9,868	10,243	11,493
Trade Receivables	8,884	9,421	9,061	10,593	11,439	11,249	13,046	15,510
Cash & Cash Equivalents	7,062	5,677	6,273	4,508	4,624	9,286	10,269	9,771
Current Investments	3,951	4,897	3,130	7,634	9,373	8,585	13,656	20,933
Loans – Current	309	148	56	170	41	65	48	53
Current Financial Assets	20,868	21,884	19,569	24,133	27,387	31,337	39,823	49,503
Other Current Assets	2,315	1,895	1,876	1,886	1,962	2,228	2,528	2,865
Other Current Financial Assets	448	929	876	702	765	917	1,741	1,404
Assets Held for Sale	—	—	—	—	21	42	30	31
Net Working Capital	13,730	15,948	14,296	17,814	19,956	26,449	34,400	41,238
Additional Asset Fields	5,868	7,036	6,573	5,952	6,484	7,543	4,675	4,356
Def Tax Assets	2,555	3,175	3,556	2,897	3,164	4,104	4,408	4,046
Non Controlling Int	3,314	3,860	3,017	3,055	3,320	3,439	268	310
Total Assets	64,694	68,252	67,667	69,800	80,744	85,463	92,101	1,08,785
Total Borrowings	9,893	7,578	3,343	931	6,198	2,846	1,870	4,082
Net Debt	2,831	1,902	-2,930	-3,578	1,574	-6,440	-8,399	-5,689
Debt to Equity (x)	0.22	0.15	0.07	0.02	0.1	0.04	0.03	0.05
Current Ratio (x)	1.79	2.02	1.89	2.04	2	2.56	2.89	2.82

Sun Pharmaceutical Industries cash flow statement

Cash generated and used across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.

Sun Pharmaceutical Industries annual cash flow statement across operating, investing and financing activities. Figures in ₹ crore unless a row states otherwise.
Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Net Cash from Operating Activities	8,985	4,959	12,135	14,072	12,419
Profit Before Tax	4,481	9,408	11,088	13,752	15,119
Depreciation & Amortisation	2,144	2,529	2,557	2,575	2,938
Finance Costs	127	172	238	231	339
Working Capital Changes	1,559	-5,662	1,062	-324	-1,268
Tax Paid	969	-1,510	-1,569	-477	-2,314
Net Cash from Investing Activities	-5,725	-7,944	-690	-5,306	-11,344
Purchase of PPE	-1,495	-2,086	-2,202	-2,129	-3,609
Sale of Fixed Assets	61	21	31	61	96
Interest Received	76	318	613	804	705
Net Cash from Financing Activities	-5,193	2,376	-6,710	-7,906	-2,513
Proceeds from Borrowings	1,657	8,160	4,716	3,362	5,322
Repayment of Borrowings	-4,293	-3,030	-8,106	-4,392	-3,410
Interest Paid	-73	-99	-219	-224	-331
Dividend Paid	-2,169	-2,520	-2,901	-3,617	-3,938
Buyback / Redemption of Shares	0	0	0	0	0
Lease Liabilities Paid	-129	-135	-123	-135	-151
Net Change in Cash	-1,765	115	4,662	983	-498
Effect of Foreign Exchange Changes	169	724	-73	123	939
Free Cash Flow	7,490	2,874	9,933	11,944	8,810
CFO / PBT (x)	2	0.53	1.09	1.02	0.82

Sun Pharmaceutical Industries key ratios

Valuation, profitability, return, leverage and per-share measures computed from reported statements — not from adjusted or normalised earnings.

Sun Pharmaceutical Industries trades at a P/E of 41.95× against a sector median of 42.68× — a 2% discount. Sector comparisons can mislead for conglomerates with mixed business lines.

Sun Pharmaceutical Industries valuation, profitability, return and leverage ratios
Ratio	Category	Value
P/E (TTM)	Valuation	41.95
Forward P/E	Valuation	29.23
P/B	Valuation	5.76
PEG (TTM)	Valuation	1.04
EV / EBITDA (TTM)	Valuation	24.18
P/S (TTM)	Valuation	8.21
Operating margin	Profitability	28.2%
Net margin (TTM)	Profitability	18.56%
Return on equity	Return ratios	16%
Return on capital employed	Return ratios	20.5%
Return on assets	Return ratios	8.43%
Debt to equity	Leverage & liquidity	0.06
Beta	Leverage & liquidity	0.53
EPS (TTM)	Per share	₹47.76
Book value	Per share	₹348.31
Revenue / share (TTM)	Per share	₹236.03
Cash flow / share	Per share	₹51.76
Dividend yield	Shareholder returns	0.8%
Dividend payout (TTM)	Shareholder returns	33.64%

How this is calculated

Statements are as filed with the exchanges. Consolidated figures are shown where reported. Figures are in rupees crore unless the table states otherwise. Ratios are computed from the same reported statements, not from adjusted or normalised earnings.

Index membership reflects the Nifty 100 as published by NSE Indices, effective 2026-03-30.

Sun Pharmaceutical Industries: frequently asked questions

What is Sun Pharmaceutical Industries's annual revenue?

Sun Pharmaceutical Industries reported revenue of ₹58,462 crore in Mar 2026, up 11.2% on the previous financial year.

Is Sun Pharmaceutical Industries profitable?

Sun Pharmaceutical Industries reported a net profit of ₹11,479 crore in Mar 2026, up 5.0% on the previous financial year.

What is Sun Pharmaceutical Industries's EPS?

Sun Pharmaceutical Industries reported earnings per share of ₹47.84 for Mar 2026.

What is Sun Pharmaceutical Industries's operating margin?

Sun Pharmaceutical Industries's operating margin for Mar 2026 was 30.33%.

What is Sun Pharmaceutical Industries's return on equity?

Sun Pharmaceutical Industries's return on equity stands at 16.00%. ROE measures profit generated per rupee of shareholder equity.

How many years of Sun Pharmaceutical Industries financials are shown?

9 reported financial years are tabulated on this page, the most recent being Mar 2026.

Are these figures consolidated or standalone?

Consolidated figures are shown wherever the company reports them, and standalone otherwise. The basis in use is labelled on the statement table.

More Sun Pharmaceutical Industries data

Compare financial statements with peers

Explore

Comparing financial statements across companies is more useful than reading one in isolation — the peer links above open the same view for Sun Pharmaceutical Industries’s closest listed competitors.

Disclaimer

The data, ratios and commentary about Sun Pharmaceutical Industries Ltd (SUNPHARMA) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.